Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.29
BMRN's Cash to Debt is ranked higher than
62% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. BMRN: 1.29 )
BMRN' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: 1.29

Equity to Asset 0.62
BMRN's Equity to Asset is ranked higher than
70% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. BMRN: 0.62 )
BMRN' s 10-Year Equity to Asset Range
Min: -0.66   Max: 0.97
Current: 0.62

-0.66
0.97
F-Score: 4
Z-Score: 6.78
M-Score: -3.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -23.66
BMRN's Operating margin (%) is ranked higher than
76% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. BMRN: -23.66 )
BMRN' s 10-Year Operating margin (%) Range
Min: -1075   Max: 13.41
Current: -23.66

-1075
13.41
Net-margin (%) -29.76
BMRN's Net-margin (%) is ranked higher than
76% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. BMRN: -29.76 )
BMRN' s 10-Year Net-margin (%) Range
Min: -1025   Max: 54.7
Current: -29.76

-1025
54.7
ROE (%) -12.77
BMRN's ROE (%) is ranked higher than
76% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. BMRN: -12.77 )
BMRN' s 10-Year ROE (%) Range
Min: -78.61   Max: 28.7
Current: -12.77

-78.61
28.7
ROA (%) -7.96
BMRN's ROA (%) is ranked higher than
78% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. BMRN: -7.96 )
BMRN' s 10-Year ROA (%) Range
Min: -80.46   Max: 16.3
Current: -7.96

-80.46
16.3
ROC (Joel Greenblatt) (%) -21.60
BMRN's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. BMRN: -21.60 )
BMRN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -347.63   Max: 16.32
Current: -21.6

-347.63
16.32
Revenue Growth (%) 10.00
BMRN's Revenue Growth (%) is ranked higher than
84% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. BMRN: 10.00 )
BMRN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 97.7
Current: 10

0
97.7
» BMRN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BMRN Guru Trades in Q3 2013

Louis Moore Bacon 62,500 sh (New)
Steven Cohen 126,339 sh (+11.91%)
John Griffin 1,750,000 sh (unchged)
PRIMECAP Management 7,606,929 sh (-1.01%)
Frank Sands 10,268,812 sh (-9.49%)
Columbia Wanger 2,360,292 sh (-12.58%)
RS Investment Management 56,200 sh (-84.58%)
» More
Q4 2013

BMRN Guru Trades in Q4 2013

Jim Simons 280,071 sh (New)
Steven Cohen 358,301 sh (+183.6%)
John Griffin 2,060,000 sh (+17.71%)
RS Investment Management Sold Out
Louis Moore Bacon Sold Out
Frank Sands 10,236,277 sh (-0.32%)
PRIMECAP Management 7,560,129 sh (-0.62%)
Columbia Wanger 2,045,000 sh (-13.36%)
» More
Q1 2014

BMRN Guru Trades in Q1 2014

Manning & Napier Advisors, Inc 171,510 sh (New)
Ray Dalio 48,400 sh (New)
John Burbank 5,173 sh (New)
PRIMECAP Management 8,163,719 sh (+7.98%)
John Griffin 2,060,000 sh (unchged)
Jim Simons Sold Out
Frank Sands 9,737,665 sh (-4.87%)
Columbia Wanger 1,389,000 sh (-32.08%)
Steven Cohen 62,853 sh (-82.46%)
» More
Q2 2014

BMRN Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 244,060 sh (+42.3%)
Frank Sands 11,925,248 sh (+22.47%)
John Griffin 2,100,000 sh (+1.94%)
Steven Cohen 90,100 sh (unchged)
Ray Dalio Sold Out
John Burbank Sold Out
PRIMECAP Management 8,064,219 sh (-1.22%)
Columbia Wanger 1,167,800 sh (-15.93%)
» More
» Details

Insider Trades

Latest Guru Trades with BMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Frank Sands 2014-06-30 Add 22.47%0.35%$56.15 - $68.61 $ 66.6510%11925248
Ray Dalio 2014-06-30 Sold Out 0.03%$56.15 - $68.61 $ 66.6510%0
John Burbank 2014-06-30 Sold Out 0.01%$56.15 - $68.61 $ 66.6510%0
Ray Dalio 2014-03-31 New Buy0.03%$64.99 - $83.28 $ 66.65-10%48400
John Burbank 2014-03-31 New Buy0.01%$64.99 - $83.28 $ 66.65-10%5173
John Griffin 2013-12-31 Add 17.71%0.23%$59.3 - $75.09 $ 66.65-2%2060000
Frank Sands 2013-09-30 Reduce -9.49%0.2%$58.64 - $78.388 $ 66.650%10268812
Meridian Funds 2013-06-30 Sold Out 0.09%$54.72 - $70.3 $ 66.657%0
Frank Sands 2013-03-31 Add 10.9%0.24%$49.2 - $62.39 $ 66.6518%10951298
Meridian Funds 2013-03-31 Reduce -69.03%0.17%$49.2 - $62.39 $ 66.6518%40700
Frank Sands 2012-12-31 Add 450.74%1.56%$36.78 - $50.17 $ 66.6546%9874728
Daniel Loeb 2012-12-31 Sold Out 0.79%$36.78 - $50.17 $ 66.6546%0
Meridian Funds 2012-12-31 Reduce -60.99%0.3%$36.78 - $50.17 $ 66.6546%131400
John Griffin 2012-12-31 Reduce -20.09%0.28%$36.78 - $50.17 $ 66.6546%1750000
John Griffin 2012-09-30 New Buy1.4%$37.23 - $43.29 $ 66.6569%2190000
Daniel Loeb 2012-09-30 New Buy0.79%$37.23 - $43.29 $ 66.6569%1000000
George Soros 2012-06-30 Sold Out 0.15%$32.53 - $38.87 $ 66.6585%0
Richard Perry 2012-06-30 Sold Out 0.04%$32.53 - $38.87 $ 66.6585%0
George Soros 2012-03-31 Add 300%0.11%$33.68 - $38.34 $ 66.65102%300000
Richard Perry 2012-03-31 New Buy0.04%$33.68 - $38.34 $ 66.65102%22900
George Soros 2011-12-31 Reduce -57.14%0.05%$30.07 - $35.38 $ 66.65103%75000
George Soros 2011-06-30 Add 862.36%0.07%$24.93 - $28.455 $ 66.65153%191510
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.70
BMRN's P/B is ranked higher than
71% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. BMRN: 6.70 )
BMRN' s 10-Year P/B Range
Min: 3.68   Max: 27.54
Current: 6.7

3.68
27.54
P/S 15.30
BMRN's P/S is ranked higher than
76% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. BMRN: 15.30 )
BMRN' s 10-Year P/S Range
Min: 3.37   Max: 94.86
Current: 15.3

3.37
94.86
EV-to-EBIT -64.83
BMRN's EV-to-EBIT is ranked higher than
59% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BMRN: -64.83 )
BMRN' s 10-Year EV-to-EBIT Range
Min: 30   Max: 67133.8
Current: -64.83

30
67133.8
Current Ratio 7.32
BMRN's Current Ratio is ranked higher than
84% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. BMRN: 7.32 )
BMRN' s 10-Year Current Ratio Range
Min: 0.9   Max: 18.94
Current: 7.32

0.9
18.94
Quick Ratio 6.16
BMRN's Quick Ratio is ranked higher than
82% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. BMRN: 6.16 )
BMRN' s 10-Year Quick Ratio Range
Min: 0.82   Max: 18.77
Current: 6.16

0.82
18.77

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 68.71
BMRN's Price/Net Current Asset Value is ranked higher than
75% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. BMRN: 68.71 )
BMRN' s 10-Year Price/Net Current Asset Value Range
Min: 3.09   Max: 1794
Current: 68.71

3.09
1794
Price/Tangible Book 7.82
BMRN's Price/Tangible Book is ranked higher than
75% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. BMRN: 7.82 )
BMRN' s 10-Year Price/Tangible Book Range
Min: 2.15   Max: 103.23
Current: 7.82

2.15
103.23
Price/DCF (Projected) 22.83
BMRN's Price/DCF (Projected) is ranked higher than
90% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BMRN: 22.83 )
BMRN' s 10-Year Price/DCF (Projected) Range
Min: 19.77   Max: 234.29
Current: 22.83

19.77
234.29
Price/Median PS Value 1.03
BMRN's Price/Median PS Value is ranked higher than
84% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. BMRN: 1.03 )
BMRN' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 10.41
Current: 1.03

0.28
10.41
Forward Rate of Return (Yacktman) -0.61
BMRN's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. BMRN: -0.61 )
BMRN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.8   Max: -2
Current: -0.61

-9.8
-2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BM8.Germany
BioMarin Pharmaceutical Inc., was incorporated in Delaware in October 1996 and began operations on March 21, 1997. It develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. The company selects product candidates for diseases and conditions that represent an unmet medical need. Its product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The company is conducting clinical trials on several investigational product candidates for the treatment of various diseases including: GALNS, an enzyme replacement therapy for the treatment of Mucopolysaccharidosis Type IV or Morquio Syndrome Type A, or MPS IV A, PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria or PKU, BMN-701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder, BMN-673, an orally available poly (ADP-ribose) polymerase, or PARP inhibitor for the treatment of patients with certain cancers and BMN-111, a peptide therapeutic for the treatment of achondroplasia. The Company is conducting preclinical development of several other enzyme product candidates for genetic and other metabolic diseases, including BMN-190 for the treatment of late infantile neuronal ceroid lipofuscinosis, or LINCL, a form of Batten disease. The Company faces competition from biological products approved through an abbreviated regulatory pathway. The Company operates in a regulated industry, which is subject to significant federal, state, local and foreign regulation.
» More Articles for BMRN

Headlines

Articles On GuruFocus.com
You Can No Longer Ignore Biotech Feb 07 2014 
Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 
BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper sells 11,250 Shares Nov 24 2010 

More From Other Websites
BioMarin Named by CenterWatch as One of the Fastest Developers of Medicines Sep 15 2014
BioMarin to Attend Upcoming Investor Conferences in London Sep 10 2014
Merck KGaA's Kuvan Effective in Under-4 Year Olds Sep 05 2014
Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Sep 03 2014
Early data suggest Sanofi, Regeneron drug may halve heart risk Aug 31 2014
Early data suggest Sanofi, Regeneron drug may halve heart risk Aug 31 2014
BioMarin Cuts '14 Revenue View after Voucher Sale Evaluation Aug 27 2014
Can BioMarin Pharmaceutical (BMRN) Run Higher on Strong Earnings Estimate Revisions? Aug 27 2014
BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Results of Operations and Financial Condition Aug 26 2014
Roche to buy U.S. biotech firm InterMune for $8.3 billion Aug 25 2014
Roche to buy U.S. biotech firm InterMune for $8.3 bln Aug 25 2014
BioMarin to Present at Upcoming Investor Conferences Aug 19 2014
BIOMARIN PHARMACEUTICAL INC Financials Aug 08 2014
Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics Corporation (SPNC), Interview with The... Aug 08 2014
NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales Aug 07 2014
BioMarin Weathers The Storm Aug 06 2014
4 Top Drugmakers Deliver Solid Doses Of Earnings Growth Aug 05 2014
BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 01 2014
BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up Jul 31 2014
BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report Jul 31 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK